ClinicalTrials.gg
Not yet recruitingNCT07950189Updated Nov 20, 2026

Smartphone Use, EMG, and Walking Accelerometry

An interventional study of Fixed-Sequence Gaze and Smartphone Tasks During Walking in Smartphone Use, Gait Balance and Postural Balance Disorders, sponsored by Kafrelsheikh University. Not yet recruiting at 1 site in Saudi Arabia. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Kafrelsheikh University · Not applicable, Interventional, and Basic science

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
All
01

Study summary

This study examines lower-limb muscle activation and smartphone-derived movement characteristics while 100 healthy university students complete five 2-minute walking conditions: forward gaze, downward gaze without a phone, passive smartphone viewing, smartphone texting, and smartphone voice recording. All participants will complete the conditions in the same fixed order, with a 2-minute seated passive-rest interval after each walking bout

02

Conditions studied

  • Smartphone Use
  • Gait Balance
  • Postural Balance Disorders
03

In context

Lead sponsor

Kafrelsheikh University is the lead sponsor of 305 studies on the registry; 122 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-30 years. Registered university student. Able to walk independently without an assistive device. Able to look at, type on, and speak into a smartphone while walking. Able to understand study instructions and provide .

Exclusion criteria

Exclusion Criteria:

  • Lower-limb or neck injury during the preceding 6 months. Diagnosed neurological disorder. Diagnosed vestibular disorder. Uncorrected visual impairment affecting safe walking or smartphone viewing. Inability to type or text comfortably. Any condition identified during screening that made walking while using a smartphone unsafe.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Single Group - Five Smartphone Walking Conditions

    A single cohort of 100 healthy university students (aged 18-30 years) completing five fixed-sequence 2-minute walking conditions (C1: Forward-gaze walking, C2: Downward-gaze walking without phone, C3: Passive smartphone viewing, C4: Smartphone texting, C5: Smartphone voice recording), with 2 minutes of seated passive rest after each walking bout.

    Behavioral: Fixed-Sequence Gaze and Smartphone Tasks During Walking

Interventions

  • BehavioralFixed-Sequence Gaze and Smartphone Tasks During Walking

    Participants perform five investigator-assigned walking tasks in a fixed order: C1, walking with forward gaze and no smartphone; C2, walking with downward gaze and no smartphone; C3, walking while passively viewing an illuminated smartphone screen; C4, walking while texting on a smartphone; and C5, walking while recording a voice message on a smartphone. Each task lasts 2 minutes, with 2 minutes of seated passive rest after each walking bout. Surface electromyography and pocket-smartphone accelerometry are recorded during each walking condition.

06

What researchers measure

Primary outcomes

  1. Mean Bilateral Tibialis Anterior-Medial Gastrocnemius (TA-MG) Co-Contraction Index

    Calculated from dynamic surface EMG amplitude recorded at 2000 Hz during steady-state walking across the five conditions.

    Time frame: Retained within each 2-minute walking bout across all 5 conditions

  2. Step Regularity

    Estimated from the first dominant autocorrelation peak of pocket-smartphone accelerometry.

    Time frame: Retained within each 2-minute walking bout across all 5 conditions

Secondary outcomes

  1. Rectus Femoris-Biceps Femoris (RF-BF) Co-Contraction Index

    Bilateral knee antagonist co-contraction index calculated from surface EMG.

    Time frame: Retained within each 2-minute walking bout across all 5 conditions

07

Study locations

1 site
  • College of Applied Medical Sciences
    Sakakah, Sakaka 23941, Saudi Arabia
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the approved ethics and participant-consent provisions do not permit sharing participant-level data outside the study team.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Feb 20, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950189
Collaborators
Jouf University
Responsible party
Ahmed Ali Mohammed Torad (Assistant Professor, Jouf University) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion